Neurological Sciences

, Volume 39, Issue 12, pp 2097–2106 | Cite as

The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis

  • Yuhan Zhu
  • Yanyan Liu
  • Jing Zhao
  • Qingqing Han
  • Lei Liu
  • Xiaoxu ShenEmail author
Original Article



This meta-analysis was performed to evaluate the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide (CGRP) for episodic migraine prevention.


MEDLINE, EMBASE, Web of Science, and the Cochrane Library were searched from inception to April 2018. Studies considered to be eligible were randomized controlled trials about efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine prevention.


Eight randomized controlled trials involving 2292 patients were included. The outcomes of this meta-analysis presented that CGRP monoclonal antibodies for preventive treatment of episodic migraine significantly reduced the monthly migraine days from baseline [weighted mean difference (WMD) = − 1.52; 95%CI, − 1.92 to − 1.11; Z = 7.40; P < 0.001] and monthly acute migraine-specific medication consumption from baseline [WMD = − 1.45; 95%CI, − 2.17 to − 0.72; Z = 3.93; P < 0.001], as compared with placebo group. CGRP monoclonal antibodies for preventive treatment of episodic migraine significantly increased the ≥ 50% reduction from baseline in migraine days per month [RR = 1.54; 95%CI, 1.38 to1.71; Z = 7.88; P < 0.001]. The adverse events were similar between the CGRP monoclonal antibody group and placebo group (P = 0.998). The outcomes of subgroup analysis showed that erenumab, galcanezumab, and fremanezumab significantly reduced the monthly migraine days from baseline and increased the ≥ 50% reduction from baseline in migraine days per month. Both erenumab and fremanezumab significantly reduced from baseline.


Based on the results of this meta-analysis, CGRP monoclonal antibodies significantly reduced the monthly migraine days and acute migraine-specific medication. CGRP monoclonal antibodies were effective and safe for preventive treatment of episodic migraine.


Calcitonin gene-related peptide monoclonal antibody Episodic migraine Meta-analysis Randomized controlled trial 


Compliance with ethical standards

This study was not registered.

Conflict of interest

The authors declare that they have no competing interests.


  1. 1.
    Headache Classification Committee of the International Headache Society (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629–808Google Scholar
  2. 2.
    Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML (2016) A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: demographics and headache-related disability. Headache 56:1280–1289CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Goadsby PJ, Sprenger T (2010) Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol 9:285–298CrossRefPubMedGoogle Scholar
  4. 4.
    Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22:54–61CrossRefPubMedGoogle Scholar
  5. 5.
    Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6(10):573–582CrossRefPubMedGoogle Scholar
  6. 6.
    Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94(4):1099–1142CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kaiser EA, Russo AF (2013) CGRP and migraine: could PACAP play a role too? Neuropeptides 47(6):451–461CrossRefPubMedGoogle Scholar
  8. 8.
    Higgins JP, Green S Cochrane handbook for systematic reviews of interventions (version 51.0). [cited 2012 Jan 5]. Available at:
  9. 9.
    Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123–2132CrossRefPubMedGoogle Scholar
  10. 10.
    Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434CrossRefPubMedGoogle Scholar
  11. 11.
    Sun H, Dodick DW, Silberstein S et al (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15(4):382–390CrossRefPubMedGoogle Scholar
  12. 12.
    Dodick DW, Goadsby PJ, Silberstein SD et al (2014) Safety and efficacy of ALD403, an antibody to calciton in gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13(9):1100–1107CrossRefPubMedGoogle Scholar
  13. 13.
    Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW (2017) Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol 75:187–193. CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Dodick DW, Goadsby PJ, Spierings ELH et al (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13:885–892CrossRefPubMedGoogle Scholar
  15. 15.
    Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, Bigal ME (2017) Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines. Headache 57(9):1375–1384CrossRefPubMedGoogle Scholar
  16. 16.
    Bigal ME, Dodick DW, Rapoport AM et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1091–1100CrossRefPubMedGoogle Scholar
  17. 17.
    Hong P, Wu X, Liu Y (2017) Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: a meta analysis. Clin Neurol Neurosurg 154:74–78CrossRefPubMedGoogle Scholar
  18. 18.
    Khan S, Olesen A, Ashina M et al (2017) CGRP, target for preventive therapy in migraine and cluster headache: systematic review of clinical data. Cephalalgia 333102417741297.Google Scholar
  19. 19.
    Mitsikostas DD, Reuter U (2017) Calcitonin gene-related peptide moncoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol 30(3):272–280CrossRefPubMedGoogle Scholar
  20. 20.
    Bigal ME, Dodick DW, Krymchantowski AV (2016) TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology 87(1):41–48CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Giamberardino MA, Affaitati G, Martelletti P et al (2015) Impact of migraine on fibromyalgia symptoms. J Headache Pain 17(1):28CrossRefPubMedGoogle Scholar
  22. 22.
    de Tommaso M, Sciruicchio V, Delussi M, Vecchio E, Goffredo M, Simeone M, Barbaro MGF (2017) Symptoms of central sensitization and comorbidity for juvenile fibromyalgia in childhood migraine: an observational study in a tertiary headache center. J Headache Pain 18(1):59CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cho SJ, Sohn JH, Bae JS, Chu MK (2017) Fibromyalgia among patients with chronic migraine and chronic tension-type headache: a multicenter prospective cross-sectional study. Headache 57(10):1583–1592CrossRefPubMedGoogle Scholar
  24. 24.
    Ferrante E (2013) Modified Valsalva test differentiates primary from secondary cough headache. J Headache Pain 14(1):1–2CrossRefGoogle Scholar
  25. 25.
    Adelborg K, Szépligeti SK, Holland-Bill L et al (2018) Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ 360:k96CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lipton RB, Reed ML, Kurth T, Fanning KM, Buse DC (2017) Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 57(10):1507–1521CrossRefPubMedGoogle Scholar
  27. 27.
    Karp BI, Sinaii N, Nieman LK, Silberstein SD, Stratton P (2011) Migraine in women with chronic pelvic pain with and without endometriosis. Fertil Steril 95(3):895–899CrossRefPubMedGoogle Scholar
  28. 28.
    Kakisaka Y, Ohara T, Katayama S, Suzuki T, Hino-Fukuyo N, Uematsu M, Kure S (2013) Another case of lower back pain associated with migraine: the importance of specific questions. J Child Neurol 28(5):680CrossRefPubMedGoogle Scholar
  29. 29.
    Yoon MS, Manack A, Schramm S, Fritsche G, Obermann M, Diener HC, Moebus S, Katsarava Z (2013) Chronic migraine and chronic tension-type headache are associated with concomitant low back pain: results of the German Headache Consortium study. Pain 154(3):484–492CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Dongzhimen Hospital Affiliated to Beijing University of Chinese MedicineBeijingChina
  2. 2.YEDA HospitalYantaiChina

Personalised recommendations